Successful Immunotherapy Rechallenge Without Recurrence of Hemophagocytic Lymphohistiocytosis in a Patient With Metastatic Endometrial Cancer Previously Treated With Dostarlimab

Authors

  • Emilie Rollet
  • Sebastien Puigrenier
  • Abeer Najem
  • Benoit Desgrousilliers
  • Pierre Riviere

DOI:

https://doi.org/10.14740/wjon2661

Keywords:

Hemophagocytic lymphohistiocytosis, Immune checkpoint inhibitors, Immunotherapy-related adverse events, Pembrolizumab, Dostarlimab, Endometrial cancer, Ruxolitinib, Corticosteroid prophylaxis

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare but potentially fatal immune hyperactivation syndrome that can be induced by immune checkpoint inhibitors (ICIs). We report a case of a 72-year-old woman with metastatic endometrial carcinoma who developed HLH after dostarlimab treatment and underwent successful immunotherapy rechallenge with pembrolizumab-lenvatinib plus prophylactic corticosteroids without HLH recurrence. Close biological monitoring ensured no relapse of HLH during rechallenge.

Author Biography

  • Emilie Rollet

    Medical Oncology Department, Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France

Downloads

Published

2025-10-10

Issue

Published Online-First

Section

Case Report

License

Copyright (c) 2025 The authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

1.
Rollet E, Puigrenier S, Najem A, Desgrousilliers B, Riviere P. Successful Immunotherapy Rechallenge Without Recurrence of Hemophagocytic Lymphohistiocytosis in a Patient With Metastatic Endometrial Cancer Previously Treated With Dostarlimab. World J Oncol. Published online October 10, 2025. doi:10.14740/wjon2661